Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Neoplasms

Explore clinical trials studying Fallopian Tube Neoplasms. Study availability and eligibility vary by location and protocol.

610 public trials 90 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Neoplasms trial results

Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations
  • University of Alabama_6th Ave Birmingham, Alabama, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber / Harvard Cancer Center Boston, Massachusetts, United States
  • Mayo Clinic - Rochester Rochester, Minnesota, United States
View all 54 locations
View Trial Details
Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326

Conditions
Adnexal Diseases, Disease Attributes, Endocrine Gland Neoplasms, +25 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • The City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • Chao Family Comprehensive Cancer Center Orange, California, United States
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
View all 28 locations
View Trial Details
Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377

Conditions
Adnexal Diseases, Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, +36 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 482 locations
View Trial Details
Recruiting

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

NCT07776691

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • MedStar Washington Hospital Center ( Site 0026) Washington D.C., District of Columbia, United States
  • Texas Oncology - DFW ( Site 8005) Fort Worth, Texas, United States
  • Sourasky Medical Center ( Site 1403) Tel Aviv, Israel
View Trial Details
Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804

Conditions
Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +23 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • HonorHealth Phoenix, Arizona, United States
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center Burbank, California, United States
  • City of Hope, Duarte Duarte, California, United States
View all 267 locations
View Trial Details
Recruiting

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Johns Hopkins Medicine SKCCC Baltimore, Maryland, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • OU Health, Stephenson Cancer Center Oklahoma City, Oklahoma, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more
Locations
  • Advent Health Orlando, Florida, United States
  • Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States
  • Washington University School of Medicine in St. Louis St Louis, Missouri, United States
  • Providence Cancer Institute Portland, Oregon, United States
View Trial Details
Recruiting

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • The University of Alabama at Birmingham Birmingham, Alabama, United States
  • UC San Diego Health La Jolla, California, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
View all 56 locations
View Trial Details
Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

NCT04575935

Conditions
Adnexal Diseases, Advanced Ovarian Carcinoma, Endocrine Gland Neoplasms, +39 more
Locations
  • University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States
  • Cleveland Clinic Foundation - Florida Weston, Florida, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 19 locations
View Trial Details

Related conditions